To this concern, notably, c-MET availability has been related with resistance to radio- and chemo-therapy in different cancer types [23,24,25], therefore it is conceivable to hypothesize that also in TGCTs, c-MET receptor activation could lead to a refractory disease. This evidence concerns the gene MET and cancer.